Needham Reiterates Buy on TransMedics Gr, Maintains $208 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on TransMedics Group (NASDAQ:TMDX) and maintained a price target of $208.
August 23, 2024 | 10:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on TransMedics Group and maintained a price target of $208, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $208 price target by a reputable analyst suggests a positive outlook for TransMedics Group. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100